A simplified bi-monthly regimen with leucovorin (LV) and 5-Fluorouracil (5FU) for metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Tournigand, C
de Gramont, A
Louvet, C
Andre, T
Carola, E
Gilles-Amar, V
Maindrault-Goebel, F
Lotz, JP
Molitor, JL
机构：
[1] Hop St Antoine, GERCOR, F-75571 Paris, France
[2] Hop Tenon, F-75970 Paris, France
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
189
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [31] COMPARATIVE PHASE 2 STUDY OF INFUSIONAL 5, 10-METHYLENETETRAHYDROFOLATE WITH 5-FLUOROURACIL (FU) VERSUS LEUCOVORIN (LV) WITH FU IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Cassidy, J.
    Jelic, S.
    Pluzanska, A.
    Ciuleanu, T.
    Babu, K. G.
    Stewart, J.
    Schupp, J. P. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [32] Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC).
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Bernuzzi, P
    Bertè, R
    Bidin, L
    Palladino, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 330S - 330S
  • [33] A randomised phase II study comparing irinotecan (IRI) plus leucovorin (LV) and 5-fluorouracil (5FU) versus IRI-LV-5FU followed be oxaliplatin (OXA) plus LV-5FU in patients with previously untreated metastatic colorectal cancer (CRC).
    Kalofonos, H. P.
    Papakostas, P.
    Aravantinos, G.
    Papadimitriou, C.
    Pentheroudakis, G.
    Varthalitis, I.
    Tsavdaridis, D.
    Syrigos, K.
    Kosmidis, P.
    Fountzilas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
  • [34] Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer
    Wang, WS
    Lin, JK
    Chiou, TJ
    Liu, JH
    Fan, FS
    Yen, CC
    Lin, TC
    Jiang, JK
    Yang, SH
    Chen, PM
    HEPATO-GASTROENTEROLOGY, 2000, 47 (36) : 1599 - 1603
  • [35] 5-FLUOROURACIL (5FU) WITH OR WITHOUT FOLINIC ACID (LV) IN HUMAN COLORECTAL-CANCER - MULTIVARIATE METAANALYSIS OF THE LITERATURE
    BROHEE, D
    MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1991, 8 (04): : 271 - 280
  • [36] A multicenter phase II study of irinotecan (CPT-11) and bolus 5-fluorouracil (5FU)/I-leucovorin (I-LV) in patients with metastatic colorectal cancer
    Fujishima, H
    Makiyama, A
    Miyanaga, O
    Ueda, A
    Esaki, T
    Mitsugi, K
    Baba, E
    Kusaba, H
    Harada, M
    Nakano, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 306S - 306S
  • [37] Adjuvant therapy with 5-fluorouracil (5FU) plus levamisole or 5FU plus radiotherapy in resected colorectal cancer.
    Aparicio, J
    Segura, A
    Santaballa, A
    Garcerá, S
    Yuste, A
    López, P
    Tormo, A
    Reynés, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S78 - S78
  • [38] Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mCRC)
    Berlin, Jordan
    Malik, Imtiaz
    Picus, Joel
    Glisson, Shawn
    Kozloff, Mark
    Spitzer, Gary
    Wiens, Brian
    MacDonald, Monica
    Jerian, Susan
    Hecht, J. Randolph
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 71
  • [39] Impact of empirically eliminating 5-fluorouracil (5-FU) bolus and leucovorin (LV) in patients with metastatic colorectal cancer (mCRC) receiving first-line treatment with mFOLFOX6.
    Basilio, Alexa
    Shah, Anand
    Sommerer, Katelyn
    Chehab, Sarah
    Bottiglieri, Salvatore Michael
    Imanirad, Iman
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in previously treated patients with advanced metastatic gastric cancer
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Anselmi, E
    Bidin, L
    Palladino, M
    Rodinò, C
    ANNALS OF ONCOLOGY, 2005, 16 : 323 - 323
12345